Stockscreener 앱 받기
101.68
4.73%
4.59
시간 외 거래:
101.68
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Receives U.S. FDA Approval - simplywall.st
PTGX Analyst Rating Update: Leerink Partners Raises Price Target to $110 | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Protagonist Therapeutics (PTGX) Receives Rating Update from JP M - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $106.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade - MarketBeat
Citigroup Raises Price Target for PTGX to $125, Maintains Buy Ra - GuruFocus
Johnson & Johnson-Protagonist Therapeutics partnered new psoriasis pill wins FDA nod, shakes up competition with AbbVie - MSN
Protagonist Therapeutics (PTGX) Sees Target Price Upgrade from B - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $119.00 Price Target at Barclays - MarketBeat
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Clear Street raises Protagonist Therapeutics price target on FDA approval By Investing.com - Investing.com Canada
Icotyde’s in; wave of switchers to oral psoriasis Protagonist? - BioWorld MedTech
How an East Bay company picked up $50 million with another $580 million potentially on the way - The Business Journals
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026 - Meyka
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
CEO Moves: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Risk Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Barclays raises Protagonist Therapeutics stock price target on FDA approval - Investing.com
Jefferies raises Protagonist Therapeutics price target on drug approval By Investing.com - Investing.com Canada
Jefferies raises Protagonist Therapeutics price target on drug approval - Investing.com
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis TreatmentSlideshow (NASDAQ:PTGX) 2026-03-18 - Seeking Alpha
Protagonist Therapeutics stock gets Truist buy rating reiterated By Investing.com - Investing.com Canada
FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment - Traders Union
J&J wins FDA nod for plaque psoriasis pill developed with Protagonist - Seeking Alpha
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis - ACCESS Newswire
FDA approves first oral IL-23 psoriasis pill, Protagonist lands $50M - Stock Titan
Protagonist Therapeutics stock hits all-time high at 98.65 USD By Investing.com - Investing.com South Africa
Protagonist Therapeutics stock hits all-time high at 98.65 USD - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighHere's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Protagonist Therapeutics (PTGX) and CG Oncology, Inc. (CGON) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
Protagonist Therapeutics, Inc. $PTGX Holdings Boosted by HighVista Strategies LLC - MarketBeat
Farallon Capital Management LLC Acquires 24,000 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Stock Holdings Lifted by Boxer Capital Management LLC - MarketBeat
Commodore Capital LP Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 96.65 USD By Investing.com - Investing.com Nigeria
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC - MarketBeat
PTGX: Lead peptide assets near approval as diversified pipeline and partnerships drive future growth - TradingView
Atika Capital Management LLC Takes $5.51 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bergen Record
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
Wall Street Recap: Is Protagonist Therapeutics Inc trading at a discount2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
PTGX: Two late-stage oral peptide drugs near approval, with strong pipeline and financial flexibility - TradingView
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Enterprise News
Responsive Playbooks and the PTGX Inflection - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighShould You Buy? - MarketBeat
Protagonist Therapeutics stock hits all-time high at 96.65 USD - Investing.com India
Nasdaq Moves: Can Protagonist Therapeutics Inc expand into new markets2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)? - Sahm
Intech Investment Management LLC Sells 12,310 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc. - MarketBeat
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - The Fayetteville Observer
Assessing Protagonist Therapeutics (PTGX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - AOL.com
Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st
JPMorgan Chase & Co. Lowers Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX: Oral IL-23 and rusfertide near launches, with strong data and major market potential ahead - TradingView
TD Cowen Health Care Conference - marketscreener.com
Protagonist Therapeutics (PTGX) Target Price Raised by Goldman S - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):